| dbo:abstract
|
- Maropitant ist ein Arzneistoff aus der Gruppe der Antiemetika (Medikamente, die Übelkeit und Brechreiz unterdrücken), der in der Veterinärmedizin verwendet wird. Aus chemischer Sicht gehört er zu den Chinuclidinaminen. Maropitant besitzt zwei Chiralitätszentren, es existieren daher vier Enantiomere. Zulassungsinhaber ist derzeit das Pharmaunternehmen Zoetis. (de)
- Maropitant es un fármaco sintético antagonista selectivo del receptor de neurokinina tipo 1 (NK1) no peptídico. (es)
- Maropitant (INN; trade name: Cerenia /səˈriːniə/ sə-REE-nee-ə), used as maropitant citrate (USAN), is a neurokinin-1 (NK1) receptor antagonist which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. It was approved by the FDA in 2007 for use in dogs and in 2012 for cats. Maropitant also has mild pain-relieving, anti-anxiety and anti-inflammatory effects. (en)
- Il maropitant, usato come maropitant citrato, è un farmaco ad uso veterinario . Viene utilizzato principalmente per ridurre la nausea ed il vomito indotto da chemioterapia. In Italia è venduto con il nome di Cerenia. Il suo uso è approvato unicamente per le specie canine. (it)
|
| dbo:alternativeName
|
- Cerenia, Prevomax, Vetemex (en)
|
| dbo:casNumber
| |
| dbo:chEMBL
| |
| dbo:class
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 20459 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:atcSuffix
| |
| dbp:atcvet
| |
| dbp:bioavailability
|
- Oral: 20–30% dogs, 50% cats (en)
- SQ: 90% (en)
|
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chembl
| |
| dbp:chemspiderid
| |
| dbp:class
| |
| dbp:dailymedid
| |
| dbp:durationOfAction
| |
| dbp:eliminationHalfLife
| |
| dbp:h
| |
| dbp:iupacName
|
- -N--2--1-azabicyclo[2.2.2]octan-3-amine (en)
|
| dbp:kegg
| |
| dbp:legalStatus
| |
| dbp:metabolism
| |
| dbp:metabolites
| |
| dbp:n
| |
| dbp:o
| |
| dbp:proteinBound
| |
| dbp:pubchem
| |
| dbp:routesOfAdministration
| |
| dbp:smiles
| |
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- PGVSXRHFXJOMGW-YBZGWEFGSA-N (en)
|
| dbp:synonyms
| |
| dbp:tradename
|
- Cerenia, Prevomax, Vetemex (en)
|
| dbp:unii
| |
| dbp:verifiedrevid
| |
| dbp:width
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- Maropitant ist ein Arzneistoff aus der Gruppe der Antiemetika (Medikamente, die Übelkeit und Brechreiz unterdrücken), der in der Veterinärmedizin verwendet wird. Aus chemischer Sicht gehört er zu den Chinuclidinaminen. Maropitant besitzt zwei Chiralitätszentren, es existieren daher vier Enantiomere. Zulassungsinhaber ist derzeit das Pharmaunternehmen Zoetis. (de)
- Maropitant es un fármaco sintético antagonista selectivo del receptor de neurokinina tipo 1 (NK1) no peptídico. (es)
- Maropitant (INN; trade name: Cerenia /səˈriːniə/ sə-REE-nee-ə), used as maropitant citrate (USAN), is a neurokinin-1 (NK1) receptor antagonist which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. It was approved by the FDA in 2007 for use in dogs and in 2012 for cats. Maropitant also has mild pain-relieving, anti-anxiety and anti-inflammatory effects. (en)
- Il maropitant, usato come maropitant citrato, è un farmaco ad uso veterinario . Viene utilizzato principalmente per ridurre la nausea ed il vomito indotto da chemioterapia. In Italia è venduto con il nome di Cerenia. Il suo uso è approvato unicamente per le specie canine. (it)
|
| rdfs:label
|
- Maropitant (de)
- Maropitant (es)
- Maropitant (it)
- Maropitant (en)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:homepage
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |